

# CD47 (IAP) Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/C49B8D504312EN.html>

Date: May 2022

Pages: 108

Price: US\$ 3,250.00 (Single User License)

ID: C49B8D504312EN

## Abstracts

This report contains market size and forecasts of CD47 (IAP) in Global, including the following market information:

Global CD47 (IAP) Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global CD47 (IAP) market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

CD47 Monoclonal Antibody Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of CD47 (IAP) include Gilead, Innovent Biologics, Akeso, Inc, Arch Oncology, ImmuneOncia Therapeutics, I-MAB, Sorrento Therapeutics, Zai Lab and ImmuneOnco, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the CD47 (IAP) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global CD47 (IAP) Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global CD47 (IAP) Market Segment Percentages, by Type, 2021 (%)

CD47 Monoclonal Antibody

CD47 Double Antibody

CD47 Fusion Protein

Global CD47 (IAP) Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global CD47 (IAP) Market Segment Percentages, by Application, 2021 (%)

Solid Tumor

Lymphoma

Others

Global CD47 (IAP) Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global CD47 (IAP) Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

## Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies CD47 (IAP) revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies CD47 (IAP) revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Gilead

Innovent Biologics

Akeso, Inc

Arch Oncology

ImmuneOncia Therapeutics

I-MAB

Sorrento Therapeutics

Zai Lab

ImmuneOnco

Hengrui

Beijing Mab-works

Hanxbio

ALX Oncology

Surface Oncology

TG Therapeutics

EpicentRx

## Contents

### **1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS**

- 1.1 CD47 (IAP) Market Definition
- 1.2 Market Segments
  - 1.2.1 Market by Type
  - 1.2.2 Market by Application
- 1.3 Global CD47 (IAP) Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
  - 1.5.1 Research Methodology
  - 1.5.2 Research Process
  - 1.5.3 Base Year
  - 1.5.4 Report Assumptions & Caveats

### **2 GLOBAL CD47 (IAP) OVERALL MARKET SIZE**

- 2.1 Global CD47 (IAP) Market Size: 2021 VS 2028
- 2.2 Global CD47 (IAP) Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
  - 2.3.1 Market Opportunities & Trends
  - 2.3.2 Market Drivers
  - 2.3.3 Market Restraints

### **3 COMPANY LANDSCAPE**

- 3.1 Top CD47 (IAP) Players in Global Market
- 3.2 Top Global CD47 (IAP) Companies Ranked by Revenue
- 3.3 Global CD47 (IAP) Revenue by Companies
- 3.4 Top 3 and Top 5 CD47 (IAP) Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies CD47 (IAP) Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 CD47 (IAP) Players in Global Market
  - 3.6.1 List of Global Tier 1 CD47 (IAP) Companies
  - 3.6.2 List of Global Tier 2 and Tier 3 CD47 (IAP) Companies

### **4 MARKET SIGHTS BY PRODUCT**

- 4.1 Overview

- 4.1.1 by Type - Global CD47 (IAP) Market Size Markets, 2021 & 2028
- 4.1.2 CD47 Monoclonal Antibody
- 4.1.3 CD47 Double Antibody
- 4.1.4 CD47 Fusion Protein
- 4.2 By Type - Global CD47 (IAP) Revenue & Forecasts
  - 4.2.1 By Type - Global CD47 (IAP) Revenue, 2017-2022
  - 4.2.2 By Type - Global CD47 (IAP) Revenue, 2023-2028
  - 4.2.3 By Type - Global CD47 (IAP) Revenue Market Share, 2017-2028

## **5 SIGHTS BY APPLICATION**

- 5.1 Overview
  - 5.1.1 By Application - Global CD47 (IAP) Market Size, 2021 & 2028
  - 5.1.2 Solid Tumor
  - 5.1.3 Lymphoma
  - 5.1.4 Others
- 5.2 By Application - Global CD47 (IAP) Revenue & Forecasts
  - 5.2.1 By Application - Global CD47 (IAP) Revenue, 2017-2022
  - 5.2.2 By Application - Global CD47 (IAP) Revenue, 2023-2028
  - 5.2.3 By Application - Global CD47 (IAP) Revenue Market Share, 2017-2028

## **6 SIGHTS BY REGION**

- 6.1 By Region - Global CD47 (IAP) Market Size, 2021 & 2028
- 6.2 By Region - Global CD47 (IAP) Revenue & Forecasts
  - 6.2.1 By Region - Global CD47 (IAP) Revenue, 2017-2022
  - 6.2.2 By Region - Global CD47 (IAP) Revenue, 2023-2028
  - 6.2.3 By Region - Global CD47 (IAP) Revenue Market Share, 2017-2028
- 6.3 North America
  - 6.3.1 By Country - North America CD47 (IAP) Revenue, 2017-2028
  - 6.3.2 US CD47 (IAP) Market Size, 2017-2028
  - 6.3.3 Canada CD47 (IAP) Market Size, 2017-2028
  - 6.3.4 Mexico CD47 (IAP) Market Size, 2017-2028
- 6.4 Europe
  - 6.4.1 By Country - Europe CD47 (IAP) Revenue, 2017-2028
  - 6.4.2 Germany CD47 (IAP) Market Size, 2017-2028
  - 6.4.3 France CD47 (IAP) Market Size, 2017-2028
  - 6.4.4 U.K. CD47 (IAP) Market Size, 2017-2028
  - 6.4.5 Italy CD47 (IAP) Market Size, 2017-2028

6.4.6 Russia CD47 (IAP) Market Size, 2017-2028

6.4.7 Nordic Countries CD47 (IAP) Market Size, 2017-2028

6.4.8 Benelux CD47 (IAP) Market Size, 2017-2028

## 6.5 Asia

6.5.1 By Region - Asia CD47 (IAP) Revenue, 2017-2028

6.5.2 China CD47 (IAP) Market Size, 2017-2028

6.5.3 Japan CD47 (IAP) Market Size, 2017-2028

6.5.4 South Korea CD47 (IAP) Market Size, 2017-2028

6.5.5 Southeast Asia CD47 (IAP) Market Size, 2017-2028

6.5.6 India CD47 (IAP) Market Size, 2017-2028

## 6.6 South America

6.6.1 By Country - South America CD47 (IAP) Revenue, 2017-2028

6.6.2 Brazil CD47 (IAP) Market Size, 2017-2028

6.6.3 Argentina CD47 (IAP) Market Size, 2017-2028

## 6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa CD47 (IAP) Revenue, 2017-2028

6.7.2 Turkey CD47 (IAP) Market Size, 2017-2028

6.7.3 Israel CD47 (IAP) Market Size, 2017-2028

6.7.4 Saudi Arabia CD47 (IAP) Market Size, 2017-2028

6.7.5 UAE CD47 (IAP) Market Size, 2017-2028

## 7 PLAYERS PROFILES

### 7.1 Gilead

7.1.1 Gilead Corporate Summary

7.1.2 Gilead Business Overview

7.1.3 Gilead CD47 (IAP) Major Product Offerings

7.1.4 Gilead CD47 (IAP) Revenue in Global Market (2017-2022)

7.1.5 Gilead Key News

### 7.2 Innovent Biologics

7.2.1 Innovent Biologics Corporate Summary

7.2.2 Innovent Biologics Business Overview

7.2.3 Innovent Biologics CD47 (IAP) Major Product Offerings

7.2.4 Innovent Biologics CD47 (IAP) Revenue in Global Market (2017-2022)

7.2.5 Innovent Biologics Key News

### 7.3 Akeso, Inc

7.3.1 Akeso, Inc Corporate Summary

7.3.2 Akeso, Inc Business Overview

7.3.3 Akeso, Inc CD47 (IAP) Major Product Offerings



- 7.3.4 Akeso, Inc CD47 (IAP) Revenue in Global Market (2017-2022)
- 7.3.5 Akeso, Inc Key News
- 7.4 Arch Oncology
  - 7.4.1 Arch Oncology Corporate Summary
  - 7.4.2 Arch Oncology Business Overview
  - 7.4.3 Arch Oncology CD47 (IAP) Major Product Offerings
  - 7.4.4 Arch Oncology CD47 (IAP) Revenue in Global Market (2017-2022)
  - 7.4.5 Arch Oncology Key News
- 7.5 ImmuneOncia Therapeutics
  - 7.5.1 ImmuneOncia Therapeutics Corporate Summary
  - 7.5.2 ImmuneOncia Therapeutics Business Overview
  - 7.5.3 ImmuneOncia Therapeutics CD47 (IAP) Major Product Offerings
  - 7.5.4 ImmuneOncia Therapeutics CD47 (IAP) Revenue in Global Market (2017-2022)
  - 7.5.5 ImmuneOncia Therapeutics Key News
- 7.6 I-MAB
  - 7.6.1 I-MAB Corporate Summary
  - 7.6.2 I-MAB Business Overview
  - 7.6.3 I-MAB CD47 (IAP) Major Product Offerings
  - 7.6.4 I-MAB CD47 (IAP) Revenue in Global Market (2017-2022)
  - 7.6.5 I-MAB Key News
- 7.7 Sorrento Therapeutics
  - 7.7.1 Sorrento Therapeutics Corporate Summary
  - 7.7.2 Sorrento Therapeutics Business Overview
  - 7.7.3 Sorrento Therapeutics CD47 (IAP) Major Product Offerings
  - 7.7.4 Sorrento Therapeutics CD47 (IAP) Revenue in Global Market (2017-2022)
  - 7.7.5 Sorrento Therapeutics Key News
- 7.8 Zai Lab
  - 7.8.1 Zai Lab Corporate Summary
  - 7.8.2 Zai Lab Business Overview
  - 7.8.3 Zai Lab CD47 (IAP) Major Product Offerings
  - 7.8.4 Zai Lab CD47 (IAP) Revenue in Global Market (2017-2022)
  - 7.8.5 Zai Lab Key News
- 7.9 ImmuneOnco
  - 7.9.1 ImmuneOnco Corporate Summary
  - 7.9.2 ImmuneOnco Business Overview
  - 7.9.3 ImmuneOnco CD47 (IAP) Major Product Offerings
  - 7.9.4 ImmuneOnco CD47 (IAP) Revenue in Global Market (2017-2022)
  - 7.9.5 ImmuneOnco Key News
- 7.10 Hengrui

- 7.10.1 Hengrui Corporate Summary
- 7.10.2 Hengrui Business Overview
- 7.10.3 Hengrui CD47 (IAP) Major Product Offerings
- 7.10.4 Hengrui CD47 (IAP) Revenue in Global Market (2017-2022)
- 7.10.5 Hengrui Key News
- 7.11 Beijing Mab-works
  - 7.11.1 Beijing Mab-works Corporate Summary
  - 7.11.2 Beijing Mab-works Business Overview
  - 7.11.3 Beijing Mab-works CD47 (IAP) Major Product Offerings
  - 7.11.4 Beijing Mab-works CD47 (IAP) Revenue in Global Market (2017-2022)
  - 7.11.5 Beijing Mab-works Key News
- 7.12 Hanxbio
  - 7.12.1 Hanxbio Corporate Summary
  - 7.12.2 Hanxbio Business Overview
  - 7.12.3 Hanxbio CD47 (IAP) Major Product Offerings
  - 7.12.4 Hanxbio CD47 (IAP) Revenue in Global Market (2017-2022)
  - 7.12.5 Hanxbio Key News
- 7.13 ALX Oncology
  - 7.13.1 ALX Oncology Corporate Summary
  - 7.13.2 ALX Oncology Business Overview
  - 7.13.3 ALX Oncology CD47 (IAP) Major Product Offerings
  - 7.13.4 ALX Oncology CD47 (IAP) Revenue in Global Market (2017-2022)
  - 7.13.5 ALX Oncology Key News
- 7.14 Surface Oncology
  - 7.14.1 Surface Oncology Corporate Summary
  - 7.14.2 Surface Oncology Business Overview
  - 7.14.3 Surface Oncology CD47 (IAP) Major Product Offerings
  - 7.14.4 Surface Oncology CD47 (IAP) Revenue in Global Market (2017-2022)
  - 7.14.5 Surface Oncology Key News
- 7.15 TG Therapeutics
  - 7.15.1 TG Therapeutics Corporate Summary
  - 7.15.2 TG Therapeutics Business Overview
  - 7.15.3 TG Therapeutics CD47 (IAP) Major Product Offerings
  - 7.15.4 TG Therapeutics CD47 (IAP) Revenue in Global Market (2017-2022)
  - 7.15.5 TG Therapeutics Key News
- 7.16 EpicentRx
  - 7.16.1 EpicentRx Corporate Summary
  - 7.16.2 EpicentRx Business Overview
  - 7.16.3 EpicentRx CD47 (IAP) Major Product Offerings

7.16.4 EpicentRx CD47 (IAP) Revenue in Global Market (2017-2022)

7.16.5 EpicentRx Key News

## **8 CONCLUSION**

## **9 APPENDIX**

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

## List Of Tables

### LIST OF TABLES

- Table 1. CD47 (IAP) Market Opportunities & Trends in Global Market
- Table 2. CD47 (IAP) Market Drivers in Global Market
- Table 3. CD47 (IAP) Market Restraints in Global Market
- Table 4. Key Players of CD47 (IAP) in Global Market
- Table 5. Top CD47 (IAP) Players in Global Market, Ranking by Revenue (2021)
- Table 6. Global CD47 (IAP) Revenue by Companies, (US\$, Mn), 2017-2022
- Table 7. Global CD47 (IAP) Revenue Share by Companies, 2017-2022
- Table 8. Global Companies CD47 (IAP) Product Type
- Table 9. List of Global Tier 1 CD47 (IAP) Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 10. List of Global Tier 2 and Tier 3 CD47 (IAP) Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 11. By Type – Global CD47 (IAP) Revenue, (US\$, Mn), 2021 & 2028
- Table 12. By Type - CD47 (IAP) Revenue in Global (US\$, Mn), 2017-2022
- Table 13. By Type - CD47 (IAP) Revenue in Global (US\$, Mn), 2023-2028
- Table 14. By Application – Global CD47 (IAP) Revenue, (US\$, Mn), 2021 & 2028
- Table 15. By Application - CD47 (IAP) Revenue in Global (US\$, Mn), 2017-2022
- Table 16. By Application - CD47 (IAP) Revenue in Global (US\$, Mn), 2023-2028
- Table 17. By Region – Global CD47 (IAP) Revenue, (US\$, Mn), 2021 & 2028
- Table 18. By Region - Global CD47 (IAP) Revenue (US\$, Mn), 2017-2022
- Table 19. By Region - Global CD47 (IAP) Revenue (US\$, Mn), 2023-2028
- Table 20. By Country - North America CD47 (IAP) Revenue, (US\$, Mn), 2017-2022
- Table 21. By Country - North America CD47 (IAP) Revenue, (US\$, Mn), 2023-2028
- Table 22. By Country - Europe CD47 (IAP) Revenue, (US\$, Mn), 2017-2022
- Table 23. By Country - Europe CD47 (IAP) Revenue, (US\$, Mn), 2023-2028
- Table 24. By Region - Asia CD47 (IAP) Revenue, (US\$, Mn), 2017-2022
- Table 25. By Region - Asia CD47 (IAP) Revenue, (US\$, Mn), 2023-2028
- Table 26. By Country - South America CD47 (IAP) Revenue, (US\$, Mn), 2017-2022
- Table 27. By Country - South America CD47 (IAP) Revenue, (US\$, Mn), 2023-2028
- Table 28. By Country - Middle East & Africa CD47 (IAP) Revenue, (US\$, Mn), 2017-2022
- Table 29. By Country - Middle East & Africa CD47 (IAP) Revenue, (US\$, Mn), 2023-2028
- Table 30. Gilead Corporate Summary
- Table 31. Gilead CD47 (IAP) Product Offerings

Table 32. Gilead CD47 (IAP) Revenue (US\$, Mn), (2017-2022)
Table 33. Innovent Biologics Corporate Summary
Table 34. Innovent Biologics CD47 (IAP) Product Offerings
Table 35. Innovent Biologics CD47 (IAP) Revenue (US\$, Mn), (2017-2022)
Table 36. Akeso, Inc Corporate Summary
Table 37. Akeso, Inc CD47 (IAP) Product Offerings
Table 38. Akeso, Inc CD47 (IAP) Revenue (US\$, Mn), (2017-2022)
Table 39. Arch Oncology Corporate Summary
Table 40. Arch Oncology CD47 (IAP) Product Offerings
Table 41. Arch Oncology CD47 (IAP) Revenue (US\$, Mn), (2017-2022)
Table 42. ImmuneOncia Therapeutics Corporate Summary
Table 43. ImmuneOncia Therapeutics CD47 (IAP) Product Offerings
Table 44. ImmuneOncia Therapeutics CD47 (IAP) Revenue (US\$, Mn), (2017-2022)
Table 45. I-MAB Corporate Summary
Table 46. I-MAB CD47 (IAP) Product Offerings
Table 47. I-MAB CD47 (IAP) Revenue (US\$, Mn), (2017-2022)
Table 48. Sorrento Therapeutics Corporate Summary
Table 49. Sorrento Therapeutics CD47 (IAP) Product Offerings
Table 50. Sorrento Therapeutics CD47 (IAP) Revenue (US\$, Mn), (2017-2022)
Table 51. Zai Lab Corporate Summary
Table 52. Zai Lab CD47 (IAP) Product Offerings
Table 53. Zai Lab CD47 (IAP) Revenue (US\$, Mn), (2017-2022)
Table 54. ImmuneOnco Corporate Summary
Table 55. ImmuneOnco CD47 (IAP) Product Offerings
Table 56. ImmuneOnco CD47 (IAP) Revenue (US\$, Mn), (2017-2022)
Table 57. Hengrui Corporate Summary
Table 58. Hengrui CD47 (IAP) Product Offerings
Table 59. Hengrui CD47 (IAP) Revenue (US\$, Mn), (2017-2022)
Table 60. Beijing Mab-works Corporate Summary
Table 61. Beijing Mab-works CD47 (IAP) Product Offerings
Table 62. Beijing Mab-works CD47 (IAP) Revenue (US\$, Mn), (2017-2022)
Table 63. Hanxbio Corporate Summary
Table 64. Hanxbio CD47 (IAP) Product Offerings
Table 65. Hanxbio CD47 (IAP) Revenue (US\$, Mn), (2017-2022)
Table 66. ALX Oncology Corporate Summary
Table 67. ALX Oncology CD47 (IAP) Product Offerings
Table 68. ALX Oncology CD47 (IAP) Revenue (US\$, Mn), (2017-2022)
Table 69. Surface Oncology Corporate Summary
Table 70. Surface Oncology CD47 (IAP) Product Offerings

Table 71. Surface Oncology CD47 (IAP) Revenue (US\$, Mn), (2017-2022)

Table 72. TG Therapeutics Corporate Summary

Table 73. TG Therapeutics CD47 (IAP) Product Offerings

Table 74. TG Therapeutics CD47 (IAP) Revenue (US\$, Mn), (2017-2022)

Table 75. EpicentRx Corporate Summary

Table 76. EpicentRx CD47 (IAP) Product Offerings

Table 77. EpicentRx CD47 (IAP) Revenue (US\$, Mn), (2017-2022)

## List Of Figures

### LIST OF FIGURES

- Figure 1. CD47 (IAP) Segment by Type in 2021
- Figure 2. CD47 (IAP) Segment by Application in 2021
- Figure 3. Global CD47 (IAP) Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global CD47 (IAP) Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global CD47 (IAP) Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by CD47 (IAP) Revenue in 2021
- Figure 8. By Type - Global CD47 (IAP) Revenue Market Share, 2017-2028
- Figure 9. By Application - Global CD47 (IAP) Revenue Market Share, 2017-2028
- Figure 10. By Region - Global CD47 (IAP) Revenue Market Share, 2017-2028
- Figure 11. By Country - North America CD47 (IAP) Revenue Market Share, 2017-2028
- Figure 12. US CD47 (IAP) Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada CD47 (IAP) Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico CD47 (IAP) Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe CD47 (IAP) Revenue Market Share, 2017-2028
- Figure 16. Germany CD47 (IAP) Revenue, (US\$, Mn), 2017-2028
- Figure 17. France CD47 (IAP) Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. CD47 (IAP) Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy CD47 (IAP) Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia CD47 (IAP) Revenue, (US\$, Mn), 2017-2028
- Figure 21. Nordic Countries CD47 (IAP) Revenue, (US\$, Mn), 2017-2028
- Figure 22. Benelux CD47 (IAP) Revenue, (US\$, Mn), 2017-2028
- Figure 23. By Region - Asia CD47 (IAP) Revenue Market Share, 2017-2028
- Figure 24. China CD47 (IAP) Revenue, (US\$, Mn), 2017-2028
- Figure 25. Japan CD47 (IAP) Revenue, (US\$, Mn), 2017-2028
- Figure 26. South Korea CD47 (IAP) Revenue, (US\$, Mn), 2017-2028
- Figure 27. Southeast Asia CD47 (IAP) Revenue, (US\$, Mn), 2017-2028
- Figure 28. India CD47 (IAP) Revenue, (US\$, Mn), 2017-2028
- Figure 29. By Country - South America CD47 (IAP) Revenue Market Share, 2017-2028
- Figure 30. Brazil CD47 (IAP) Revenue, (US\$, Mn), 2017-2028
- Figure 31. Argentina CD47 (IAP) Revenue, (US\$, Mn), 2017-2028
- Figure 32. By Country - Middle East & Africa CD47 (IAP) Revenue Market Share, 2017-2028
- Figure 33. Turkey CD47 (IAP) Revenue, (US\$, Mn), 2017-2028
- Figure 34. Israel CD47 (IAP) Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia CD47 (IAP) Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE CD47 (IAP) Revenue, (US\$, Mn), 2017-2028

Figure 37. Gilead CD47 (IAP) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Innovent Biologics CD47 (IAP) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Akeso, Inc CD47 (IAP) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Arch Oncology CD47 (IAP) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. ImmuneOncia Therapeutics CD47 (IAP) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. I-MAB CD47 (IAP) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Sorrento Therapeutics CD47 (IAP) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Zai Lab CD47 (IAP) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. ImmuneOnco CD47 (IAP) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Hengrui CD47 (IAP) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 47. Beijing Mab-works CD47 (IAP) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 48. Hanxbio CD47 (IAP) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 49. ALX Oncology CD47 (IAP) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 50. Surface Oncology CD47 (IAP) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 51. TG Therapeutics CD47 (IAP) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 52. EpicentRx CD47 (IAP) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)



## I would like to order

Product name: CD47 (IAP) Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/C49B8D504312EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C49B8D504312EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970